Limited therapeutic efficacy and drug resistance in advanced-stage prostate cancer contributes to poor outcomes, highlighting the need for targeted therapies with alternative mechanisms of action. Here, we leveraged human-centric AI to accelerate target identification for prostrate adenocarcinoma.

Early-stage triple-negative breast cancer (TNBC) primarily relies on surgery and chemotherapy, yet its response is often suboptimal compared to other breast cancer subtypes. The development of targeted therapies is crucial to improve prognosis, enhance treatment efficacy and mitigate drug resistance. Identifying novel therapeutic pathways holds the potential to transform TNBC treatment.

Despite available treatments for blood cancer, achieving sufficient dosage at the tumor site for therapeutic efficacy is difficult, underscoring the crucial need for improved targeted therapies. Here we used Causaly to identify and prioritize potential targets for Diffuse Large B Cell Lymphoma (DLBCL) – the most prevalent Non-Hodgkin Lymphoma.     

Bladder cancer treatments are hampered by high recurrence, requiring multiple therapeutic interventions which are highly invasive and cause side effects, underscoring the need for innovative treatments. In the pursuit of advancing bladder cancer treatment, immuno-oncology shows promise. This blog delves into the importance of identifying antigens in the development of targeted cancer therapies.  

Ubiquitination plays a key role in the pathophysiology of multiple myeloma, highlighting its promise as a therapeutic target for this plasma cell malignancy. In this blog, we used Causaly to explore genetic alterations affecting by ubiquitination in multiple myeloma.

Understanding GOF mutations is crucial for developing targeted therapies which inhibit the activity of aberrant proteins. Here, we explored FLT3 and NOTCH1 as GOF mutations associated with leukemia disease progression.

miRNA therapeutics face numerous challenges including targeted delivery, specificity, stability, immune response, and toxicity. Overcoming these challenges is paramount for success.

Head and neck cancers account for nearly 4% of all cancers in the US. The most common type is oral cancer, estimated to cause over 170,000 global deaths in 2020 alone. These statistics highlight the urgent need for more research and better treatments.

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.